Are Ideas Getting Harder to Find?
In many growth models, economic growth arises from people creating ideas, and the long-run growth rate is the product of two terms: the effective number of researchers and their research [...]
How do Patents Affect Follow-On Innovation? Evidence from the Human Genome
We investigate whether patents on human genes have affected follow-on scientific research and product development. Using administrative data on successful and unsuccessful patent applications submitted to the US Patent and [...]
Foreign Competition and Domestic Innovation: Evidence from US Patents
The competitive shock to the U.S. manufacturing sector spurred by rising China import competition could either catalyze or stifle innovation. Using three distinct sources of variation to identify rising trade [...]
Effects of Copyrights on Science – Evidence from the US Book Republication Program
Copyrights for books, news, and other types of media are a critical mechanism to encourage creativity and innovation. Yet economic analyses continue to be rare, partly due to a lack [...]
The U.S. Patent System, not China’s IP Policies, is the Reason Behind America’s Decline in Global Competitiveness
China has established courts that specialize in intellectual property litigation so litigants have an experienced, fast and cost-effective forum to resolve patent disputes. These specialist courts take about 10 months [...]
The Unpredictable Prospects of Patenting Cancer Innovation
There is great variability with respect to patenting cancer innovation. Cancer patent application allowance rates range from 20.5% to 100.0%, with even similarly situated Art Units showing a wide disparity.Kate [...]
Is There a Role for Patents in the Financing of Innovative Firms?
It is argued by many that one of the benefits of the patent system is that it creates a property right to invention that enables firms to obtain financing for [...]
FDA wants to help unproductive drugmakers
Given the rapid pace of scientific advances in medicine, you might think Big Pharma is in rude health. You would be wrong. Last year consultants at Deloitte estimated that returns [...]
Follow the Money: Is the U.S. patent system is fostering investment and risk taking?
The accused infringer perspective is that this state of affairs is good, that the “sky is not falling” (to use Mark Lemley’s often repeated conference statements), and that inventors, universities, [...]
Regulation and Welfare: Evidence from Paragraph IV Generic Entry in the Pharmaceutical Industry
With increasing frequency, generic drug manufacturers in the United States are able to challenge the monopoly status of patent-protected drugs even before their patents expire. The legal foundation for these [...]